Renowned Reproductive Medicine Clinic VCRM and INVO Bioscience Announce the Launch of the INVOcell™ Intravaginal Culture System in the Washington DC Metro Area

INVOcell™ is used for fertilization and early embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, INVOcell utilizes the woman's body as a natural incubator making it an in vivo procedure. The INVOcell procedure has a lower cost because it uses natural or low stimulation and is a more simplified procedure combined with a streamlined approach to medical management.  Yet, produces pregnancy and live birth rates similar to traditional IVF treatments. 

Dr. Sharara, Founder and Medical Director where the INVO treatment will be offered, commented, "We are very excited to offer the INVO treatment to our patients. Many of whom cannot afford to proceed with regular IVF and therefore are either left to undergo more failed IUI cycles or just drop out of treatment altogether. Some other couples feel that IVF is "not natural" or have moral or religious concerns with regular IVF, and INVO treatment is ideally suited for them. Recent data are very encouraging in that in good prognosis couples receiving the INVO treatment have success rates equal to those of traditional IVF. We believe that INVO treatment will allow couples who are struggling with emotional and financial issues an opportunity to become parents."

"There are an estimated 195,000 infertile couples in the Washington DC Metro Area that currently suffer from infertility.  The Center for Disease Control data shows that approximately 12,000 IVF cycles have been performed annually in the area leaving many patients untreated due to the cost of IVF," noted Katie Karloff, CEO of INVO Bioscience.  "Dr. Fady Sharara of the Virginia Center for Reproductive Medicine, now offering the INVOcell and INVO procedure, will be able to expand care to patients in the DC Metroplex area by providing a less expensive treatment with equivalent pregnancy rates to traditional IVF.  Dr. Sharara is the first physician to offer the INVO procedure in the Mid-Atlantic region of the U.S. as we continue to expand the offering of the INVO throughout the United States. This is very exciting for the company and promising to fertility patients.  INVO Bioscience is committed to rapidly delivering INVOcell through additional partnerships with physicians and through our own corporate facilities across the U.S."

About the Virginia Center for Reproductive Medicine

About Dr. Sharara: Dr. Sharara is a world-renowned expert in the field of Reproductive Endocrinology and Infertility. His practice (VCRM) is located in Reston, Virginia and has a reputation for consistently posting one of the highest success rates for ART on the East Coast. The clinic prides itself on its "boutique" setting along with its personalized and customized treatment plans. Dr. Sharara regularly treats patients from around the globe and the clinic has become the go-to place for many patients who have failed to achieve success at other fertility centers.

*A comparison of clinic success rates may not be meaningful because patient medical characteristics, treatment approaches, and entry criteria for ART may vary from clinic to clinic.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kathleen Karloff, CEO, INVO Bioscience, Inc. 978-878-9505 ext. 504

Dr. Fady I. Sharara, Founder and Medical Director, Virginia Center for Reproductive Medicine. (703) 437-7722

Photo - http://photos.prnewswire.com/prnh/20160501/362048

Logo - http://photos.prnewswire.com/prnh/20160418/356831LOGO 

SOURCE INVO Bioscience, Inc.

Related Links

http://www.invobioscience.com